<DOC>
	<DOCNO>NCT03009292</DOCNO>
	<brief_summary>Study E7080-C086-108 open-label , single- multiple-dose pharmacokinetic ( PK ) study lenvatinib ( administer orally , day [ QD ] ) Chinese participant solid tumor . A total 12 participant enrolled evaluate PK 24 milligram ( mg ) QD dose lenvatinib .</brief_summary>
	<brief_title>Pharmacokinetic Study E7080/Lenvatinib Chinese Subjects With Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Lenvatinib</mesh_term>
	<criteria>Participants histological and/or cytological diagnosis solid tumor Participants solid tumor resistant standard antitumor therapy , appropriate treatment available Participants whose toxicity previous treatment recover Grade 1 low ( except alopecia ) Participants complete previous antitumor therapy ( surgery , radiotherapy ) least 4 week treatment Participants 18 year old time obtain inform consent Participants Eastern Cooperative Oncology Group ( ECOG ) Performance Status ( PS ) 0 1 Participants meet following item : Hemoglobin ≥9.0 gram per deciliter ( g/dL ) Neutrophil count ≥1.5×10^3/microliters ( µL ) Platelet count ≥10×10^4/µL Total bilirubin ≤1.8 milligram ( mg ) /dL Aspartate aminotransferase ( AST ) ≤100 International Units per liter ( IU/L ) Alanine aminotransferase ( ALT ) ≤100 IU/L Serum creatinine ≤1.5 mg/dL creatinine clearance ≥50 milliliter per minute ( mL/min ) . Creatinine clearance calculate base CockcroftGault method use follow formula : Male : ( 140−age ) × weight ÷ ( serum creatinine × 72 ) ; Female : 0.85 × ( 140−age ) × weight ÷ ( serum creatinine × 72 ) . Participants expect survive 12 week longer Males females childbearing potential must agree use appropriate contraception give consent 30 day study drug administration . Female participant childbearing potential must test negative pregnancy screen Participants voluntarily agree participate study write Participants brain metastasis accompany clinical symptom require treatment Participants follow complication medical history 1 . Systemic severe infection require medical treatment 2 . The following cardiovascular disease 1 . Ischemic cardiac disease arrhythmia require medical treatment 2 . Angina pectoris myocardial infarction within 24 week enrollment 3 . Corrected QT interval ( QTc ) great 480 millisecond ( msec ) ( Fridericia 's method ) 3 . Hemoptysis ( fresh blood ) ≥ 1/2 teaspoon ( 2.5 mL ) clinically significant hemorrhagic thrombotic event within 4 week enrollment 4 . Systolic pressure ≥150 millimeter mercury ( mmHg ) diastolic pressure ≥90 mmHg 5 . If proteinuria ≥2+ qualitative test urine protein , ≥1.0 grams 24 hour accumulate 6 . Complications surgery ( malabsorption syndrome , chronic diarrhea , total gastrectomy ) could significantly influence absorption investigational drug 7 . Have undergone major surgery within 4 week enrollment 8 . Coexisting effusion require treatment Participants unable take oral medication Participants schedule surgery project course study Participants test positive human immunodeficiency virus ( HIV antibody ) , positive hepatitis B surface ( HBs antigen ) hepatitis C virus ( HCV antibody ) Participants take lenvatinib Participants view principal investigator subinvestigator able comply protocol psychiatric physical disease include alcoholism drug addiction Pregnant nursing participant Participants participate another clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>solid tumor</keyword>
	<keyword>Lenvatinib</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>